Executives from Raziel Therapeutics, an Israel-based biotech company, visited 365mc ahead of their participation in the 26th World Knowledge Forum’s side event “K-BIO NIGHT 2025,” held in Seoul earlier this month.

365mc said that the executives toured its flagship Seoul 365mc Hospital and the dedicated LAMS Hospital, which specializes in its proprietary Local Anesthesia Minimal-Invasive Liposuction (LAMS) procedure.

Raziel and 365mc are co-developing a combined body-contouring solution that integrates 365mc’s minimally invasive LAMS liposuction with Raziel’s novel fat-dissolving injectable, RZL-012. During the visit, both sides held in-depth discussions on medium- to long-term cooperation, overseas market expansion, and joint global projects leveraging the synergy of RZL-012 with LAMS.

The delegation toured the 15-story Seoul 365mc Hospital, reviewing its surgical infrastructure, sterile operating rooms meeting international standards, a 3D body-shape analysis system, and an artificial intelligence platform for predicting liposuction outcomes.

Raziel Therapeutics Chairman Philippe Sejour praised the facilities, saying, “It was very meaningful to witness firsthand 365mc’s advanced obesity treatment infrastructure and differentiated system.”

Without doubt, this partnership will deliver significant results on the global stage, Sejour added.

Sejour also served as a keynote speaker at K-BIO NIGHT, sharing strategies for globalizing K-bio.

Drawing on his past experience at Allergan, where he led major mergers and acquisitions, he highlighted aesthetic medicine as a frontier of innovation.

“Just as Allergan bundled fat-dissolving agents with Botox and developed loyalty programs to secure long-term customers, Korean companies also need strategies to strengthen consumer loyalty,” he said.

He directly referenced the Raziel–365mc partnership in his speech, noting that 365mc’s focus on fat-reduction technology is a disruptive approach in the biopharmaceutical paradigm.

Raziel’s RZL-012 has demonstrated up to a 34 percent fat reduction after a single injection and is preparing to enter phase 3 clinical trials in the U.S. Combined with LAMS, the therapy is expected to enable both broad fat dissolution and precise contouring, offering a comprehensive new model for body shaping.

365mc is working with Raziel to commercialize RZL-012 in Korea while jointly targeting major overseas markets.

Given the dominance of the U.S. in the global aesthetics market, 365mc is also accelerating its American expansion.

The company recently invited medical staff from its soon-to-open Los Angeles branch to Korea for LAMS training and is considering further expansion into key U.S. cities such as Seattle, New York, and Chicago.

“This visit was an opportunity to directly showcase our 22 years of expertise in obesity treatment to our partners,” 365mc CEO Kim Nam-chul said. “It strengthened mutual trust and will serve as a foundation for even greater collaborative synergies.”

Sejour also added, “The World Knowledge Forum provided a meaningful platform to announce the Raziel–365mc collaboration on the global stage and to exchange visions with leading biopharma executives.”

Building on the strengths of both companies, Raziel will push beyond existing limits to set a new global standard in body contouring, he added.

The 26th World Knowledge Forum was held Sept. 9–11 at the Shilla Hotel in Seoul under the theme of global cooperation and innovation, featuring prominent speakers including Jared Diamond, professor at UCLA and author of “Guns, Germs, and Steel,” and former Canadian Prime Minister Justin Trudeau.

The side event, K-BIO NIGHT 2025, gathered around 100 leaders from the pharmaceutical and biotech industries to discuss AI diagnostics, drug development, cell therapies, and strategies for global expansion.